United States · Bill · HR
H.R. 3810 (118th)
Drug Origin Transparency Act of 2023
Introduced
5 June 2023
Last action
—
Status
Referred to the Subcommittee on Health.
Sponsors
—
Subjects
Discovery layer
Source updated
27 May 2025
Summary
Drug Origin Transparency Act of 2023 This bill requires drug manufacturers to report on the suppliers of ingredients used in their products. Specifically, drug manufacturers must report information relating to the supply chain of their products, including the suppliers of active ingredients and the amount of drugs that are manufactured using those ingredients. Drug manufacturers must also include information about the manufacturers of ingredients on the labels of their products.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
3 official files
Introduced in House (text)
Introduced in House (text)
Introduced in House · EN · 5 June 2023
Introduced in House (PDF)
Introduced in House · EN · 5 June 2023
Introduced in House
summary · EN · 5 June 2023
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/118th-congress/house-bill/3810
- Open data entity: https://api.congress.gov/v3/bill/118/hr/3810